The article by Modjtahedi et al1 in this issue of JAMA Ophthalmology is noteworthy because it adds to a growing body of evidence that suggests that extending screening intervals to 2 years for those with no or minimal diabetic retinopathy (DR) at baseline may be safe and appropriate. There is an increasing need for screening intervals to be informed by evidence and tailored to risk, given the aging population and the growing burden of diabetes.
van Wijngaarden P, Keel S, Scanlon PH. The Case for Extended Screening Intervals for People With Diabetes and No or Minimal Retinopathy at Baseline. JAMA Ophthalmol. Published online February 07, 2019. doi:10.1001/jamaophthalmol.2018.6901
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: